What are the indications, recommended dosing, contraindications, required monitoring, drug interactions, common adverse effects, and alternative therapies for zafirlukast in chronic asthma management?

Zafirlukast for Chronic Asthma Management

Primary Indication

Zafirlukast is indicated for prophylaxis and chronic treatment of asthma in adults and children ≥5 years of age, but it is positioned as an alternative, not preferred, therapy for mild persistent asthma (Step 2 care). 1 The drug should never be used as monotherapy when inhaled corticosteroids (ICS) are indicated, as ICS remain the most effective long-term control medication at all steps of persistent asthma care. 2

Recommended Dosing

• Adults and children ≥12 years: 20 mg twice daily 1
• Children 5-11 years: 10 mg twice daily 1
• Elderly patients (≥65 years): Consider dose adjustment due to 2-3 fold higher drug exposure 1

Critical administration requirement: Take at least 1 hour before or 2 hours after meals, as food significantly decreases bioavailability. 2

Position in Asthma Treatment Algorithm

Zafirlukast functions as a leukotriene receptor antagonist (LTRA) that interferes with inflammatory mediators released from mast cells, eosinophils, and basophils. 2 However, its clinical positioning is limited:

• Step 2 (mild persistent asthma): Alternative option only—ICS are preferred 2
• Step 3+ (adjunctive therapy with ICS): Not preferred compared to adding long-acting beta-agonists (LABAs) in patients ≥12 years 2
• May be considered when patients have poor inhaler technique or compliance issues with inhaled medications 3, 4

Contraindications and Critical Warnings

Absolute Contraindications

• Active hepatic dysfunction 1
• Breastfeeding mothers (drug is excreted in breast milk) 1

Black Box Concerns

Hepatotoxicity is the most serious risk—liver failure resulting in death and liver transplantation has occurred. 2, 1 Patients must be warned to immediately report symptoms of hepatic dysfunction including:

• Right upper quadrant abdominal pain
• Nausea, fatigue, lethargy
• Pruritus, jaundice
• Flu-like symptoms, anorexia 1

Churg-Strauss syndrome has been reported, particularly during corticosteroid dose reduction. 1, 3 Monitor closely for:

• Systemic eosinophilia
• Eosinophilic pneumonia
• Vasculitic rash
• Cardiac complications
• Neuropathy 1

Required Monitoring

1. Hepatic enzymes (ALT): Monitor at baseline and periodically; discontinue if liver dysfunction develops 2
2. Neuropsychiatric symptoms: Screen for insomnia, depression, behavioral changes 1
3. Eosinophil counts if reducing corticosteroid doses 1
4. Prothrombin time (PT) if on warfarin—close monitoring mandatory 1

Significant Drug Interactions

Warfarin interaction is clinically critical: Zafirlukast inhibits cytochrome P450 2C9, causing a 63% increase in warfarin AUC and 35% increase in PT. 1 Anticoagulant dose adjustment is required with close PT monitoring.

Exercise caution with other CYP2C9 substrates:

• Phenytoin
• Tolbutamide
• Carbamazepine 1

Common Adverse Effects

The drug is generally well-tolerated with adverse event profile similar to placebo. 5, 6 Most common effects include:

• Headache
• Pharyngitis
• Abdominal pain
• Dyspepsia
• Cough 6

In elderly patients (≥65 years): Higher frequency of infections (7.0% vs 2.9% placebo), though typically mild lower respiratory tract infections not requiring discontinuation. 1

Alternative Therapies (Preferred Options)

For Step 2 mild persistent asthma:

• Low-dose ICS (preferred first-line) 2
• Cromolyn sodium (alternative)
• Nedocromil (alternative)
• Theophylline (alternative) 2

For adjunctive therapy with ICS:

• LABA + ICS combination (preferred in patients ≥12 years) 2

Clinical efficacy comparison: Inhaled fluticasone propionate 88 mcg or salmeterol 42 mcg twice daily demonstrated superior efficacy to zafirlukast 20 mg twice daily, though zafirlukast still showed clinical improvement over placebo. 5

Clinical Pearls and Pitfalls

• Never use for acute asthma exacerbations—zafirlukast is not a bronchodilator 1
• Do not discontinue other asthma medications when starting zafirlukast without physician guidance 1
• Patient compliance may be higher with oral zafirlukast versus inhaled therapies, making it useful when inhaler technique is problematic 3, 4
• The drug can attenuate exercise-induced bronchospasm, though less effectively than ICS 2
• Pregnancy category B, but use only if clearly needed 1